Author & Year Published

Sample size (N) and median age (A)

Diagnosis

Treatment & Dosage

Duration

Primary Outcomes Assessed

Results

Lanctôt K, et al. (2013) [17]

N = 60

(M:23; F:37)

A = 76

Mild to moderate Alzheimer's Disease

Methylphenidate

(10 mg) PO BID

6 weeks

DS

AES

DS (p = 0.03)

AES from baseline

(p = 0.06)

Padala P, et al. (2018) [14]

N = 60

A = 76

Mild Alzheimer's Disease

Methylphenidate

(10 mg) PO BID

12 weeks

AES; MMSE NPI; CGI; ZBS

AES (p = 0.001)

MMSE (2.6, 95% CI = 1.1-4.0, p = 0.001) NPI (2.3, 95% CI = 0.7-3.9, p = 0.005)

CGI (-1.3, 95% CI = -1.9 to -0.6, p ≤ 0.001)

ZBS (-5.8, 95% CI = -10.1 to -1.4, p = 0.011)

Mintzer J, et al. (2021) [18]

N = 200

(M:131; F:68)

A = 76

Mild to moderate Alzheimer's Disease

Methylphenidate

(10 mg) PO BID

6 months

NPI ADCS- CGIC

NPI

mean difference = -1.25; 95% CI, -2.03 to

-0.47; P = 0.002

ADCS-CGIC

Odds ratio 1.90 (95% CI, 0.95-3.84; P = 0.07)

Takemoto M, et al. (2020) [15]

N = 33

(M:10; F:23)

A = 77

Alzheimer's

Disease

Sertraline (31.8 mg)

Escitalopram

(7.3 mg)

Nicergoline (14.5 mg)

3 months

AS; MMSE; HDS-R; GDS

AS baseline (20.8 ± 5.2) to 3 months (16.8 ± 6.1)

p = 0.05 with Sertraline

GDS (8.2 + 3.5) to 3 months (5.7 + 2.6)

p = 0.04 with Escitalopram

Frakey L, et al. (2012) [19]

N = 23

A = 75

Mild to moderate Alzheimer's Disease

Modafinil 200 mg OD

8 weeks

FrSBe

ADLQ

DAFS

ZBS

FrSBe (p = 0.932)

ADLQ (p = 0.611)

DAFS (p = 0.465)

ZBS (p = 0.053)

Maier F, et al. (2020) [20]

N = 108

(M:67; F:41) A = 75

Mild to moderate Alzheimer's Disease

Bupoprion 150 mg OD × 4 wks then 300 mg OD × 8 wks

12 weeks

AES-C

AES-C

mean change, 2.22; 95% CI, -0.47 to 4.91; p = 0.11